Last reviewed 2026-04-22 · How we verify

Lavasept 0.04%

Lavasept is an antimicrobial skin antiseptic that kills bacteria and other microorganisms through oxidative damage.

Lavasept is an antimicrobial skin antiseptic that kills bacteria and other microorganisms through oxidative damage. Used for Skin antisepsis and infection control in wound care, Perioperative skin preparation.

At a glance

Mechanism of action

Lavasept contains polyhexamethylene biguanide (PHMB), a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid microbial death. It is formulated as a 0.04% solution for topical use in infection control and wound care settings. The mechanism provides fast-acting antimicrobial activity with low systemic toxicity due to minimal skin penetration.

Approved indications

• Skin antisepsis and infection control in wound care
• Perioperative skin preparation

Common side effects

• Skin irritation
• Contact dermatitis
• Hypersensitivity reactions

Key clinical trials

• Polihexanide SSIs Measures Bundle (PSMB) During Enhanced Recovery After Major Digestive Surgery (PHASE4)
• Reduction of Postoperative Wound Infections by Antiseptica? (PHASE3)
• Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects (PHASE1)
• The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lavasept 0.04% CI brief — competitive landscape report
• Lavasept 0.04% updates RSS · CI watch RSS
• B. Braun Ltd. Centre of Excellence Infection Control portfolio CI